New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis. Xu JX, Zhu QL, Bi YM, Peng YC, et al. BMC Cancer 2024;24:691.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xu JX, Zhu QL, Bi YM, Peng YC, et al. New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis. BMC Cancer 2024;24:691.
PMID: 38844880